Health Has pancreatic cancer met its match? Frontline researcher sees newly approved medication as ‘critical first step’ toward transformation of care Alvin Powell Harvard Staff Writer September 9, 2026 7 min read Brian Wolpin. Last month, the Food and Drug Administration approved a new drug for one of the deadliest cancers, lending new hope to patients whose treatment options had been severely limited. The drug, daraxonrasib, doubled survival time for patients with previously treated metastatic pancreatic cancer to a median of 13.2 months from 6.7 months for those who received the chemotherapy standard of care. According to the National Cancer Institute, more than 67,000 people will be diag...